Review Article
A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer
Translational Breast Cancer Research
2022;
3:
4
(31 January 2022)
Review Article
Role of abemaciclib in primary breast cancer: a narrative review of MonarchE
Translational Breast Cancer Research
2022;
3:
3
(31 January 2022)
Review Article
Innovation drug approvals based on a bridging study: from concept to practice
Translational Breast Cancer Research
2022;
3:
2
(31 January 2022)
Meet the Professor
The legend of MONARCH: Chinese breast cancer experts from participation in to leading global clinical study and boosting treatment area development
Translational Breast Cancer Research
2022;
3:
1
(31 January 2022)
Consensus
Chinese expert consensus on coronavirus disease 2019 vaccination for breast cancer patients
Translational Breast Cancer Research
2021;
2:
34
(31 October 2021)
Case Report
Case report: rare breast tumor—Schwannoma of the breast
Translational Breast Cancer Research
2021;
2:
33
(31 October 2021)
Case Report
More than 14 years’ progress free survival of neratinib monotherapy for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer: a case report
Translational Breast Cancer Research
2021;
2:
32
(31 October 2021)
Editorial Commentary
DESTINY-Breast01 Trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer
Translational Breast Cancer Research
2021;
2:
31
(31 October 2021)
Review Article
Current understandings and prospects of antibody-drug conjugates (ADCs) for the treatment of breast cancer: a narrative review
Translational Breast Cancer Research
2021;
2:
30
(31 October 2021)
Review Article
A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer
Translational Breast Cancer Research
2021;
2:
29
(31 October 2021)
Review Article
Sacituzumab govitecan in breast cancer
Translational Breast Cancer Research
2021;
2:
28
(31 October 2021)
Review Article
A narrative review of human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates in the treatment of breast cancer
Translational Breast Cancer Research
2021;
2:
27
(31 October 2021)
Meet the Professor
We are on the right road | A brief history of breast cancer guidelines in China
Translational Breast Cancer Research
2021;
2:
26
(31 July 2021)
Editorial Commentary
Neoadjuvant chemotherapy choices from population selection to regimen design: the St. Gallen International Expert Consensus Conference 2021
Translational Breast Cancer Research
2021;
2:
25
(31 July 2021)
Editorial Commentary
Updated interpretation for early breast cancer in The Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines
Translational Breast Cancer Research
2021;
2:
24
(31 July 2021)
Original Article
Development and validation of a nomogram for predicting the status of estrogen receptor-low-positive breast cancer
Translational Breast Cancer Research
2021;
2:
23
(31 July 2021)
Review Article
2021 updates in postoperative radiotherapy section of Chinese Society of Clinical Oncology Breast Cancer guideline
Translational Breast Cancer Research
2021;
2:
22
(31 July 2021)
Review Article
St. Gallen 2021 Chinese expert perspective of optimal regional management
Translational Breast Cancer Research
2021;
2:
21
(31 July 2021)
Review Article
A review of endocrine therapy in early estrogen receptor-positive breast cancer by St. Gallen Breast Cancer Conference 2021
Translational Breast Cancer Research
2021;
2:
20
(31 July 2021)
Review Article
Optimizing HER2-positive breast cancer therapy through neoadjuvant platforms: controversies and concepts
Translational Breast Cancer Research
2021;
2:
19
(31 July 2021)
Review Article
Introduction to the key contents of the Chinese Society of Breast Surgery Practice Guideline 2021
Translational Breast Cancer Research
2021;
2:
18
(31 July 2021)
Review Article
Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021
Translational Breast Cancer Research
2021;
2:
17
(31 July 2021)
Case Report
A case report of primary squamous cell carcinoma of the breast
Translational Breast Cancer Research
2021;
2:
16
(30 April 2021)
Case Report
T-DM1 for advanced breast cancer after multi-anti-HER2-target therapy: a case report
Translational Breast Cancer Research
2021;
2:
15
(30 April 2021)
Case Report
Benefit with re-challenge of immune checkpoint inhibitors in patient with metastatic triple-negative breast cancer: a case report
Translational Breast Cancer Research
2021;
2:
14
(30 April 2021)